Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
HH

NYSE · HHLA

HH&L Acquisition Co.

Financial Services · Shell Companies

$10.75

Down-$0.03 (-0.23%)

Updated Aug 17, 2026, 12:07 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
156.83M
P/E ratio
13.96
Dividend yield
0.00%
52-week range
— – —
Volume
3.4K
Avg. volume
58.92K

Price performance

HHLA price history

1M range · 0 trading sessions · Daily adjusted prices

HHLA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest HHLA news

The latest Smart Investors Daily articles mentioning HHLA.

Stock researchCompany · Overview

HHLA research

Overview

Company profile and research snapshot.

Company profile

HH&L Acquisition Co. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on healthcare or healthcare-related companies in Asian markets. The company was incorporated in 2020 and is based in Central, Hong Kong.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · May 9, 2023

DiaCarta Receives Accreditation by the College of American Pathologists (CAP)

PLEASNTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta’s leadership and commitment to excellence.

GlobeNewswire Inc. · Apr 16, 2023

DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.

GlobeNewswire Inc. · Jan 12, 2023

DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By